| Literature DB >> 32550818 |
Renata Zrinski Topić1, Jasna Leniček Krleža1.
Abstract
INTRODUCTION: The aim of this study was to examine whether the Canadian Laboratory Initiative on Paediatric Reference Intervals (CALIPER) could be applied to Croatian children and adolescents.Entities:
Keywords: hormone; immunoassay; paediatric; reference value
Mesh:
Substances:
Year: 2020 PMID: 32550818 PMCID: PMC7271758 DOI: 10.11613/BM.2020.020710
Source DB: PubMed Journal: Biochem Med (Zagreb) ISSN: 1330-0962 Impact factor: 2.313
CALIPER reference intervals verified on the Croatian children and adolescents
| M, F | 1 - < 13 | 60.4 – 353.0 | 0 | 0 | 112.7 – 293.8 | |
| M, F | 13 - < 16 | 83.6 – 472.0 | 0 | 0 | 132.7 – 438.4 | |
| M, F | 16 - < 18 | 104.0 – 535.0 | 1 | 0 | 280.5 – 476.3 | |
| M, F | 1 - < 6 | < 1.01 | 3 | 0 | 0.05 – 0.60 | |
| M, F | 6 - < 9 | 0.13 – 2.55 | 0 | 1 | 0.10 – 2.60* | |
| M, F | 9 - < 13 | 0.43 – 5.62 | 0 | 0 | 0.60 – 5.10 | |
| M | 13 - < 16 | 1.79 – 11.29 | 0 | 1 | 1.60 – 11.10* | |
| M | 16 - < 18 | 3.06 – 16.60 | 0 | 0 | 3.20 – 9.60 | |
| F | 13 - < 16 | 1.03 – 9.13 | 0 | 0 | 2.20 – 8.70 | |
| F | 16 - < 18 | 1.97 – 16.10 | 1 | 0 | 3.80 – 11.00 | |
| M, F | 1 - < 16 | 10.3 – 55.8 | 0 | 2 | 5.8 – 37.4* | |
| M | 16 - < 18 | 18.7 – 102.0 | 0 | 0 | 25.6 – 88.0 | |
| F | 16 - < 18 | 3.2 – 75.1 | 0 | 0 | 4.8 – 42.5 | |
| M | 1 - < 9 | 0.23 – 2.32 | 1 | 0 | 0.34 – 1.37 | |
| M | 9 - < 12 | 0.56 – 4.98 | 1 | 1 | 0.53 – 2.20* | |
| M | 12 - < 18 | 1.26 – 7.40 | 3 | 0 | 1.61 – 5.23 | |
| F | 1 - < 9 | 0.62 – 6.37 | 1 | 3 / 0 | 0.45 – 6.61† / 1.02 – 5.16‡ | |
| F | 9 - < 12 | 0.91 – 7.83 | 1 | 0 | 0.99 – 5.04 | |
| F | 12 - < 18 | 0.59 – 10.20 | 0 | 0 | 1.54 – 9.23 | |
| M, F | 1 - < 5 | < 2.14 | 1 | 0 | < 0.20 | |
| M, F | 5 - < 10 | < 1.67 | 2 | 0 | 0.20 – 0.34 | |
| M | 10 - < 14 | < 3.28 | 0 | 0 | 0.20 – 3.12 | |
| M | 14 - < 18 | 0.81 – 8.96 | 0 | 0 | 1.26 – 6.20 | |
| F | 10 - < 14 | < 8.09 | 3 | 0 | 0.20 – 6.70 | |
| F | 14 - < 18 | 1.59 – 19.00 | 0 | 0 | 1.89 – 14.88 | |
| M, F | 1 - < 9 | < 2.73 | 0 | 1 | 0.49 – 2.79* | |
| M, F | 9 - < 13 | < 4.48 | 0 | 0 | 0.53 – 4.08 | |
| M | 13 - < 18 | 0.60 – 5.22 | 0 | 0 | 0.85 – 4.68 | |
| F | 13 - < 18 | 0.80 – 38.5 | 1 | 0 | 1.04 – 4.66 | |
| M, F | 1 - < 18 | 3.21 – 18.50 | 2 | 1 | 2.81 – 13.92* | |
| M, F | 1 - < 8 | 53.2 – 174.0 | 0 | 2 | 59.9 – 182.6* | |
| M, F | 8 - < 11 | 45.4 – 144.0 | 0 | 3 / 0 | 32.0 – 177.9† / 46.3 – 110.1‡ | |
| M, F | 11 - < 13 | 15.9 – 132.0 | 1 | 0 | 18.8 – 97.1 | |
| M | 13 - < 18 | 10.5 – 75.3 | 0 | 0 | 12.5 – 49.4 | |
| F | 13 - < 18 | 18.1 – 95.8 | 0 | 0 | 21.8 – 85.4 | |
| M, F | 1.5 - < 7 | < 0.35§ | 0 | 0 | < 0.35§ | |
| M, F | 7 - < 9 | < 0.62 | 0 | 0 | < 0.35§ | |
| M, F | 9 - < 12 | < 1.63 | 0 | 0 | 0.35 – 0.87 | |
| M | 12 - < 18 | 0.38 – 19.60 | 0 | 0 | 0.73 – 17.48 | |
| F | 12 - < 15 | < 2.26 | 0 | 0 | 0.35 – 2.25 | |
| F | 15 - < 18 | 0.62 – 2.98 | 0 | 1 | 0.95 – 3.37* | |
| M, F | 1 - < 12 | 1.84 – 3.12 | 0 | 1 | 1.80 – 2.70* | |
| M | 12 - < 16 | 1.77 – 3.16 | 0 | 0 | 1.80 – 2.70 | |
| F | 12 - < 16 | 1.54 – 3.00 | 0 | 0 | 1.60 – 2.40 | |
| M, F | 16 - < 18 | 1.51 – 2.95 | 1 | 0 | 1.70 – 2.30 | |
| M, F | 1 - < 4 | 76 – 168 | 0 | 0 | 93 – 144 | |
| M, F | 4 - < 14 | 70 – 130 | 0 | 0 | 83 – 130 | |
| M | 14 - < 18 | 68 – 119 | 0 | 0 | 73 – 119 | |
| F | 14 - < 18 | 75 – 141 | 0 | 0 | 84 - 136 | |
| M, F | 1 - < 12 | 0.79 – 5.85 | 1 | 0 | 1.33 – 4.01 | |
| M, F | 12 - < 18 | 0.68 – 3.35 | 0 | 0 | 1.07 – 3.21 | |
| M - male. F - female. *The results measured in our study with less than 3 out of 20 samples outside the CALIPER reference interval. †the results measured in our study with 3 out of 20 samples outside the CALIPER reference interval. ‡the results measured in our study in the additional group of reference subjects. §results below the lower limit of detection (LLD) of the immunoassay denoted with „< LLD“. DHEAS - dehydroepiandrosterone sulfate. FSH - follicle stimulating hormone. LH - lutein stimulating hormone. SHBG - sex hormone binding globulin. TSH - thyroid stimulating hormone. T4 - total thyroxine. T3 - total triiodothyronine. | ||||||
Comparison of preanalytical factors
| Reference population | Canadian | Croatian |
| Subject type | healthy community | hospital outpatients |
| Sampling approach | direct | direct ( |
| Time of blood collection | all day | from 8 to 10 am |
| Blood sampling tube | serum separator tube | serum separator tube |
| Separation and aliquoting of serum | within 4 h | within 4 h |
| Serum storage | - 80°C | - 20°C (up to 2 months) |